Gilead Sciences GILD has outperformed the market over the past 20 years by 3.95% on an annualized basis producing an average annual return of 12.29%. Currently, Gilead Sciences has a market ...

In the latest quarter, 15 analysts provided ratings for Gilead Sciences (NASDAQ:GILD), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. Chris Schott has given his Buy rating due to a ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%.

Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion.

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average annual return of 12.35%. Currently, Gilead Sciences has a market ...